New cell therapy trial offers hope for tough lupus cases
NCT ID NCT06530849
First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 21 times
Summary
This study is testing an experimental injection called GC012F in people with systemic lupus erythematosus (SLE) that hasn't responded well to standard treatments. Researchers will enroll 118 participants to check if the treatment is safe and if it helps reduce lupus symptoms over 48 weeks. The study is open-label, meaning everyone receives the treatment, and focuses on people who have already tried multiple lupus medications without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGShanghai, China
-
Research Site
ACTIVE_NOT_RECRUITINGWuhan, 430060, China
Conditions
Explore the condition pages connected to this study.